Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis

Journal of Infection and Chemotherapy

Volumn 19, Issue 5, 2013, Pages 941-945

  Takahashi, Satoshi ^a,b   Hamasuna, Ryoichi ^b,c   Yasuda, Mitsuru ^b,d   Ito, Shin ^b,e   Ito, Kenji ^f   Kawai, Shuichi ^g   Yamaguchi, Takamasa ^h   Satoh, Takashi ⁱ   Sunaoshi, Kenichi ^j   Takeda, Koichi ^j   Suzuki, Nobukazu ^j   Maeda, Shinichi ^k   Nishimura, Hirofumi ^l   Fukuda, Souichirou ^m   Matsumoto, Tetsuro ^b,c  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Japanese Research Group for UTI   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d GIFU UNIVERSITY   (Japan)

^e IClinic   (Japan)

^f Ito Urology Clinic   (Japan)

^g Kawai Urology Clinic   (Japan)

^h Yamaguchi Dermatology and Urology Clinic   (Japan)

ⁱ Nisshin Urologic Clinic   (Japan)

^j Teine Urologic Clinic   (Japan)

^k TOYOTA MEMORIAL HOSPITAL   (Japan)

^l Nishimura Urology Clinic   (Japan)

^m Fukuda Clinic   (Japan)

more..

Author keywords

Chlamydia trachomatis; Mycoplasma genitalium; Sitafloxacin; Ureaplasma urealyticum; Urethritis

Indexed keywords

SITAFLOXACIN;

ADULT; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM DETECTION; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL URETHRITIS; CLINICAL EFFECTIVENESS; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MYCOPLASMA GENITALIUM; MYCOPLASMOSIS; NONHUMAN; NONSPECIFIC URETHRITIS; NUCLEIC ACID AMPLIFICATION; PROSPECTIVE STUDY; TREATMENT DURATION; UREAPLASMA UREALYTICUM;

ADULT; ANTI-BACTERIAL AGENTS; CHLAMYDIA TRACHOMATIS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOPLASMA GENITALIUM; PROSPECTIVE STUDIES; UREAPLASMA UREALYTICUM; URETHRITIS; YOUNG ADULT;

EID: 84885948177     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0620-y     Document Type: Article

References (27)

1. Takahashi S, Takeyama K, Kunishima Y, Takeda K, Suzuki N, Nishimura M, et al. Analysis of clinical manifestations of male patients with urethritis. J Infect Chemother. 2006;12:283-6.
2. Takahashi S, Matsukawa M, Kurimura Y, Takeyama K, Kunishima Y, Iwasawa A, et al. Clinical efficacy of azithromycin for male nongonococcal urethritis. J Infect Chemother. 2008;14:409-12.
3. Takahashi S, Ichihara K, Hashimoto J, Kurimura Y, Iwasawa A, Hayashi K, et al. Clinical efficacy of levofloxacin 500 mg once daily for 7 days for patients with non-gonococcal urethritis. J Infect Chemother. 2011;17:392-6.
4. Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis. 2009;48:1649-54.
5. Workowski KA, Berman S, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1-110.
6. Deguchi T, Maeda S. Mycoplasma genitalium: another important pathogen of nongonococcal urethritis. J Urol. 2002;167:1210-7.
7. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:1546-53.
8. Hamasuna R, Takahashi S, Kiyota H, et al. Effect of gatifloxacin against Mycoplasma genitalium-related urethritis: an open clinical trial. Sex Transm Infect. 2011;87:389-90.
9. Miyashita N, Niki Y, Matsushima T. In vitro and in vivo activities of sitafloxacin against Chlamydia spp. Antimicrob Agents Chemother. 2001;45:3270-2.
10. Hamasuna R, Jensen JS, Osada Y. Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. Antimicrob Agents Chemother. 2009;53:4938-9.
11. Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992;36:1491-8.
12. Ito S, Yasuda M, Seike K, et al. Clinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with a 100-mg twice-daily dose regimen of sitafloxacin. J Infect Chemother. 2012;18:414-8.
13. Yasuda M, Takahashi S, Kiyota H, et al. Japanese guideline for clinical research of antimicrobial agents on urogenital infections: the first edition. J Infect Chemother. 2011;17:579-94.
14. Mygind T, Birkelund S, Birkebæk NH, et al. Determination of PCR efficiency in chelex-100 purified clinical samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae. BMC Microbiol. 2002;2:17.
15. Jensen JS, Bjornelius E, Dohn B, Lidbrink P. Use of TaqMan 5′ nuclease real-time PCR for quantitative detection of Mycoplasma genitalium DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. J Clin Microbiol. 2004;42:683-92.
16. Hamasuna R, Osada Y, Jensen JS. Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5′ nuclease real-time PCR. Antimicrob Agents Chemother. 2005;49:4993-8.
17. Hamasuna R, Osada Y, Jensen JS. Isolation of Mycoplasma genitalium from first-void urine specimens by coculture with Vero cells. J Clin Microbiol. 2007;45:847-50.
18. Jensen JS, Borre MB, Dohn B. Detection of Mycoplasma genitalium by PCR amplification of the 16S rRNA gene. J Clin Microbiol. 2003;41:261-6.
19. Wang SA, Papp JR, Stamm WE, Peeling RW, Martin DH, Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis. 2005;191:917-23.
20. Yasuda M, Maeda S, Deguchi T. In vitro activity of fluoroquinolones against Mycoplasma genitalium and their bacteriological efficacy for treatment of M. genitalium-positive nongonococcal urethritis in men. Clin Infect Dis. 2005;41:1357-9.
21. Manhart LE. Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis 2012 http://cid.oxfordjournals.org/content/ early/2012/12/28/cid.cis1022.full.pdf+html (Accessed 16 Jan 2013).
22. Hamasuna R. Identification of treatment strategies for Mycoplasma genitalium-related urethritis in male patients by culturing and antimicrobial susceptibility testing. J Infect Chemother 2012 http://link.springer.com/ content/pdf/10.1007%2Fs10156-012-0487-3 (Accessed 16 Jan 2013).
23. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother. 2000;45:437-46.
24. Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother. 2000;44:1102-7.
25. Bebear CM, de Barbeyrac B, Pereyre S, Renaudin H, Clerc M, Bebear C. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect. 2008;14:801-5.
26. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS. 2008;19:676-9.
27. Fujita J. Niki Y, Kadota J, et al. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial. J Infect Chemother 2012 http://link.springer.com/content/pdf/10.1007%2Fs10156-012- 0514-4 (accessed 16 Jan 2013).